Search Results - "Scheffold C"

Immunotherapy of B-cell malignancies with genetically engineered human CD8⁺ natural killer T cells.

Authors: Pieper, M. Scheffold, C. Duwe, S. et al.

Source: Leukemia (08876924). Apr2006, Vol. 20 Issue 4, p729-732. 4p. 1 Chart.

Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+donor cell chimerism analysis.

Authors: Scheffold, C. Kroeger, M. Zuehlsdorf, M. et al.

Source: Leukemia (08876924). Dec2004, Vol. 18 Issue 12, p2048-2050. 3p.

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.

Authors: Motzer, R.J. Albiges, L. Treviño Aguirre, S.A. et al.

Source: Annals of Oncology. Jun2026, Vol. 37 Issue 6, p861-871. 11p.

Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.

Authors: Motzer, R.J. Escudier, B. Burotto, M. et al.

Source: Annals of Oncology. Jan2026, Vol. 37 Issue 1, p33-43. 11p.

The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab.

Authors: Kornacker, Martin Verneris, M. R. Kornacker, B. et al.

Source: Cytotherapy (Taylor & Francis Ltd). Feb2006, Vol. 8 Issue 1, p13-23. 11p. 5 Graphs.

33 Poster Discussion - XL092, a multi-targeted inhibitor of MET, VEGFR2, AXL and MER with an optimized pharmacokinetic profile.

Authors: Hsu, J. Chong, C. Goon, L. et al.

Source: European Journal of Cancer. 2020 Supplement 2, Vol. 138, pS16-S16. 1p.

872PPhase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced renal cell carcinoma (RCC).

Authors: Agarwal, N Vaishampayan, U Green, M et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

2117 - Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR).

Authors: Schmidinger, M. Motzer, R.J. Powles, T. et al.

Source: European Journal of Cancer. Feb2017 Supplement 1, Vol. 72, pS187-S188. 1p.

O4 - Patient outcomes based on prognostic risk groups in METEOR, a randomized phase 3 study of cabozantinib (cabo) versus everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).

Authors: Powles, T. Motzer, R.J. Escudier, B. et al.

Source: European Urology Supplements. Dec2016, Vol. 15 Issue 13, pe1546-e1547. 1p.

Mode Equivalence of Interactive Voice Response (IVR) and Paper Versions of the Brief Pain Inventory (BPI) “Worst Pain” Item in Metastatic Castrate Resistant Prostate Cancer (mCRPC) Evaluated Conceptually Using Qualitative Methods.

Authors: Bennett, A. Eremenco, S. Heon, N. et al.

Source: Value in Health. Nov2013, Vol. 16 Issue 7, pA601-A601. 1p.

Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesothelioma.

Authors: Möhrmann L Werner M Oleś M et al.

Source: ESMO open [ESMO Open] 2025 Apr; Vol. 10 (4), pp. 104532. Date of Electronic Publication: 2025 Apr 01.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.

Authors: Powles T Choueiri TK Motzer RJ et al.

Source: BMC cancer [BMC Cancer] 2021 Sep 15; Vol. 21 (1), pp. 1023. Date of Electronic Publication: 2021 Sep 15.

Publication Type: Published Erratum

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE; PubMed not MEDLINE

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.

Authors: Powles T Burotto M Escudier B et al.

Source: ESMO open [ESMO Open] 2024 May; Vol. 9 (5), pp. 102994. Date of Electronic Publication: 2024 Apr 20.

Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.

Authors: Neal JW Santoro A Gonzalez-Cao M et al.

Source: JTO clinical and research reports [JTO Clin Res Rep] 2024 Mar 20; Vol. 5 (10), pp. 100666. Date of Electronic Publication: 2024 Mar 20 (Print Publication: 2024).

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.

Authors: Powles T Choueiri TK Motzer RJ et al.

Source: BMC cancer [BMC Cancer] 2021 Aug 07; Vol. 21 (1), pp. 904. Date of Electronic Publication: 2021 Aug 07.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.

Authors: George DJ Hessel C Halabi S et al.

Source: The oncologist [Oncologist] 2019 Nov; Vol. 24 (11), pp. 1497-1501. Date of Electronic Publication: 2019 Aug 09.

Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE

Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.

Authors: Pal SK Albiges L Tomczak P et al.

Source: Lancet (London, England) [Lancet] 2023 Jul 15; Vol. 402 (10397), pp. 185-195. Date of Electronic Publication: 2023 Jun 05.

Publication Type: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.

Authors: Yau T Zagonel V Santoro A et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Mar 20; Vol. 41 (9), pp. 1747-1757. Date of Electronic Publication: 2022 Dec 13.

Publication Type: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.

Authors: Apolo AB Powles T Escudier B et al.

Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2022 Dec; Vol. 177, pp. 63-71. Date of Electronic Publication: 2022 Oct 04.

Publication Type: Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.

Authors: Motzer RJ Powles T Burotto M et al.

Source: The Lancet. Oncology [Lancet Oncol] 2022 Jul; Vol. 23 (7), pp. 888-898. Date of Electronic Publication: 2022 Jun 07.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE